IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension (PAH) is characterised by progressive remodelling of the pulmonary vasculature, leading to increased pulmonary vascular resistance and right heart failure. Despite advances in targeted therapies, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, and prostacyclin analogues, the prognosis for many patients remains poor.¹ There is an ongoing need for novel agents that can address different pathophysiological pathways or offer improved efficacy and safety profiles. The development of new treatments for rare diseases like PAH often faces challenges related to patient recruitment, trial duration, and the heterogeneity of disease progression. Adaptive trial designs offer a potential solution to these challenges by allowing for modifications to the study protocol based on interim data, thereby optimising resource allocation and potentially accelerating drug development.²

The IKT-001 Adaptive Study Programme

The IKT-001 adaptive clinical study programme for Pulmonary Arterial Hypertension was presented at ATS 2026, focusing on its methodological framework rather than specific efficacy outcomes. The programme is designed to evaluate IKT-001, a novel investigational agent, in patients with PAH. The core principle of the adaptive design is to permit pre-specified modifications to the trial, such as sample size adjustments, dose selection, or even endpoint modifications, based on analyses of accumulating data while maintaining statistical integrity.³

The programme includes multiple phases, beginning with an initial dose-finding and safety assessment phase. This phase is structured to identify optimal dosing regimens for IKT-001 based on pharmacokinetic, pharmacodynamic, and preliminary safety data. Subsequent phases incorporate elements of response-adaptive randomisation, where the probability of assigning patients to more effective treatment arms increases as evidence accumulates. This approach aims to maximise the number of patients receiving beneficial treatment within the trial, which is particularly relevant in conditions with high unmet medical need like PAH.⁴

Key features of the IKT-001 adaptive programme include interim analyses for futility and efficacy. Futility analyses allow for early termination of the study if the investigational drug is unlikely to demonstrate a clinically meaningful benefit, thereby conserving resources and preventing unnecessary patient exposure. Efficacy analyses, conversely, may trigger early stopping for overwhelming benefit or allow for sample size re-estimation to achieve adequate statistical power. The primary endpoint for the pivotal phase of the programme is anticipated to be a composite measure reflecting clinical worsening, such as hospitalisation for PAH, initiation of new PAH-specific therapy, or all-cause mortality. Secondary endpoints are expected to include changes in 6-minute walk distance (6MWD), N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and pulmonary vascular resistance (PVR).⁵

The programme’s adaptive nature extends to its statistical methodology, employing Bayesian approaches for continuous data monitoring and decision-making. This allows for the incorporation of prior knowledge and provides a more flexible framework for updating probabilities of treatment effects. The presentation at ATS 2026 detailed the statistical models and simulation studies used to validate the adaptive design, demonstrating its robustness and ability to control Type I error rates.⁶

While the presentation focused on the design principles, the implications for drug development in PAH are substantial. Adaptive trials can potentially reduce the overall time and cost associated with bringing new therapies to market. They also offer ethical advantages by allowing for more patients to receive effective treatments and by reducing the number of patients exposed to ineffective or harmful interventions. However, the complexity of adaptive designs requires careful planning, rigorous statistical oversight, and transparent reporting to ensure validity and interpretability of results. The IKT-001 programme represents a contemporary application of these methodologies in a challenging therapeutic area.